1. In Vivo
  2. >>Archive

Are Placebo Trials a Wave of the Future in Medical Devices?

In the wake of a study (reported in the "The New England Journal of Medicine") that arthroscopic surgery in patients delivered no better results than did a placebo procedure, industry executives are asking, "What role should placebo trials play in assessing the clinical value of medical devices or device-driven procedures?

Fresh on the heels of reports of a study from the Women's Health Initiative, which suggested that long-term hormone replacement therapy leads to increased risks of breast cancer, stroke, and heart attack, comes news of a long-term study, reported in The New England Journal of Medicine, that found that arthroscopic surgery in patients with osteoarthritis delivered no better results than did a placebo procedure.

Appearing at nearly the same time, the two studies seemed to echo each other, casting doubt on long-standing treatments with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.